Sandoz Group Ag S/Adr (SDZNY) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning ladies and gentlemen and welcome to the Sandoz call today. I will now pass on to Craig Marks, Head of Investor Relations for his opening remarks. Thank you and welcome to the Sandoz H1 2026 results call. Earlier today we published a media release and an accompanying presentation on our website which will follow on today's call. You can find these documents at sandoz.com stroke investors. Joining me on today's call are Richard Saynor, Chief Executive Officer, and Remco Steenbergen, Chief Financial Officer. Please turn to slide two. Our results, announcement, presentation, and discussion include forward-looking statements. Please see our disclaimer here. Please turn to slide three. Richard will begin today's presentation with the highlights of the company's performance in the first half of the year, followed by an update on the business. Remco will give more detail on the financial performance. as well as a recap on guidance for 2026. Following a wrap-up of the presentation, we'll be happy to take your questions. And with that, I will now hand over to Richard. Please turn to slide four. Thank you, Craig. And hello, everybody. It's a pleasure to welcome you all on the call today. Before we turn to our H1 performance, I'd like to take a moment to reflect on the growth of Sandoz. Over recent months, we've continued to strengthen our position as the global leader in affordable medicines and as an increasingly important voice in healthcare policy and medicine security. Alongside the three anniversaries shown on the slide, we're also approaching another important milestone. We are delighted that Sandoz will join the Blue Chip Swiss Market Index in September, less than three years after becoming an independent company. This is a strong recognition of our executio...